Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 2
2003 1
2004 1
2005 2
2006 1
2007 3
2008 1
2009 7
2010 8
2011 14
2012 6
2013 12
2014 14
2015 15
2016 11
2017 16
2018 10
2019 15
2020 12
2021 9
2022 18
2023 12
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

174 results

Results by year

Filters applied: . Clear all
Page 1
Liposarcoma: Multimodality Management and Future Targeted Therapies.
Crago AM, Dickson MA. Crago AM, et al. Surg Oncol Clin N Am. 2016 Oct;25(4):761-73. doi: 10.1016/j.soc.2016.05.007. Epub 2016 Jul 30. Surg Oncol Clin N Am. 2016. PMID: 27591497 Free PMC article. Review.
There are 3 biologic groups of liposarcoma: well-differentiated and dedifferentiated liposarcoma, myxoid/round cell liposarcoma, and pleomorphic liposarcoma. ...Improved understanding of the genetic aberrations that lead to liposarcoma initiatio …
There are 3 biologic groups of liposarcoma: well-differentiated and dedifferentiated liposarcoma, myxoid/round cell liposar …
Dedifferentiated Liposarcoma: Systemic Therapy Options.
Gahvari Z, Parkes A. Gahvari Z, et al. Curr Treat Options Oncol. 2020 Feb 5;21(2):15. doi: 10.1007/s11864-020-0705-7. Curr Treat Options Oncol. 2020. PMID: 32026050 Review.
Over the last several years, the systemic treatment landscape for dedifferentiated liposarcoma (DDLPS) has notably expanded. Historically, systemic therapy options have been limited to cytotoxic chemotherapy agents, including doxorubicin, ifosfamide, gemcitabine, and docet …
Over the last several years, the systemic treatment landscape for dedifferentiated liposarcoma (DDLPS) has notably expanded. Historic …
Options for treating different soft tissue sarcoma subtypes.
Ray-Coquard I, Serre D, Reichardt P, Martín-Broto J, Bauer S. Ray-Coquard I, et al. Future Oncol. 2018 May;14(10s):25-49. doi: 10.2217/fon-2018-0076. Future Oncol. 2018. PMID: 29768052 Review.
Management of soft tissue sarcoma is increasingly subtype-dependent. Surgery is recommended for uterine leiomyosarcoma, with trabectedin being the preferred option for advanced disease when the treatment goal is long-term tumor stabilization. Liposarcoma subg …
Management of soft tissue sarcoma is increasingly subtype-dependent. Surgery is recommended for uterine leiomyosarcoma, with trabe …
Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.
Pautier P, Italiano A, Piperno-Neumann S, Chevreau C, Penel N, Firmin N, Boudou-Rouquette P, Bertucci F, Balleyguier C, Lebrun-Ly V, Ray-Coquard I, Kalbacher E, Bardet A, Bompas E, Collard O, Isambert N, Guillemet C, Rios M, Archambaud B, Duffaud F; French Sarcoma Group. Pautier P, et al. Lancet Oncol. 2022 Aug;23(8):1044-1054. doi: 10.1016/S1470-2045(22)00380-1. Epub 2022 Jul 11. Lancet Oncol. 2022. PMID: 35835135 Clinical Trial.
BACKGROUND: Metastatic leiomyosarcomas have a poor prognosis, and currently doxorubicin alone is used as the standard first-line treatment. Doxorubicin combined with trabectedin has shown promising results in phase 1 and 2 studies. We aimed to identify and compare the prog …
BACKGROUND: Metastatic leiomyosarcomas have a poor prognosis, and currently doxorubicin alone is used as the standard first-line treatment. …
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.
Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, Milhem M, Elias A, Ganjoo K, Tawbi H, Van Tine BA, Spira A, Dean A, Khokhar NZ, Park YC, Knoblauch RE, Parekh TV, Maki RG, Patel SR. Demetri GD, et al. J Clin Oncol. 2016 Mar 10;34(8):786-93. doi: 10.1200/JCO.2015.62.4734. Epub 2015 Sep 14. J Clin Oncol. 2016. PMID: 26371143 Free PMC article. Clinical Trial.
PURPOSE: This multicenter study, to our knowledge, is the first phase III trial to compare trabectedin versus dacarbazine in patients with advanced liposarcoma or leiomyosarcoma after prior therapy with an anthracycline and at least one additional syst …
PURPOSE: This multicenter study, to our knowledge, is the first phase III trial to compare trabectedin versus dacarbazine in p …
Doxorubicin combined with Trabectedin in systemic first-line M+/recurrent leiomyosarcoma patients.
Turinetto M, Meeus P, Ray-Coquard I. Turinetto M, et al. Curr Opin Oncol. 2023 Jul 1;35(4):288-291. doi: 10.1097/CCO.0000000000000961. Epub 2023 May 18. Curr Opin Oncol. 2023. PMID: 37222199 Review.
PURPOSE OF REVIEW: Currently, the only systemic therapy approved for advanced leiomyosarcoma is Doxorubicin-based monotherapy. ...For the first time, the randomized phase III LMS-04 demonstrated that Doxorubicin and Trabectedin have a better PFS and di …
PURPOSE OF REVIEW: Currently, the only systemic therapy approved for advanced leiomyosarcoma is Doxorubicin-based monotherapy. …
Myxoid Liposarcomas: Systemic Treatment Options.
Nassif EF, Keung EZ, Thirasastr P, Somaiah N. Nassif EF, et al. Curr Treat Options Oncol. 2023 Apr;24(4):274-291. doi: 10.1007/s11864-023-01057-4. Epub 2023 Feb 28. Curr Treat Options Oncol. 2023. PMID: 36853469 Review.
Myxoid/round-cell liposarcoma (MRCL) account for 30% of liposarcomas and are the most chemo-sensitive subtype of liposarcoma. ...The overall response rate (ORR) by RECIST with anthracycline-based chemotherapy is around 40% and with trabectedin is 20%, althoug …
Myxoid/round-cell liposarcoma (MRCL) account for 30% of liposarcomas and are the most chemo-sensitive subtype of liposarcoma. …
Treatment of De-Differentiated Liposarcoma in the Era of Immunotherapy.
Zhou MY, Bui NQ, Charville GW, Ganjoo KN, Pan M. Zhou MY, et al. Int J Mol Sci. 2023 May 31;24(11):9571. doi: 10.3390/ijms24119571. Int J Mol Sci. 2023. PMID: 37298520 Free PMC article. Review.
This review highlights the clinical trials with developmental therapeutics that have been completed or are ongoing, including CDK4/6 inhibitors, MDM2 inhibitors, and immune checkpoint inhibitors. This review will also discuss the current landscape in assessin …
This review highlights the clinical trials with developmental therapeutics that have been completed or are ongoing, including …
Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups.
Gronchi A, Palmerini E, Quagliuolo V, Martin Broto J, Lopez Pousa A, Grignani G, Brunello A, Blay JY, Tendero O, Diaz Beveridge R, Ferraresi V, Lugowska I, Merlo DF, Fontana V, Marchesi E, Braglia L, Donati DM, Palassini E, Bianchi G, Marrari A, Morosi C, Stacchiotti S, Bagué S, Coindre JM, Dei Tos AP, Picci P, Bruzzi P, Casali PG. Gronchi A, et al. J Clin Oncol. 2020 Jul 1;38(19):2178-2186. doi: 10.1200/JCO.19.03289. Epub 2020 May 18. J Clin Oncol. 2020. PMID: 32421444 Clinical Trial.
PURPOSE: To determine whether the administration of histology-tailored neoadjuvant chemotherapy (HT) was superior to the administration of standard anthracycline plus ifosfamide neoadjuvant chemotherapy (A+I) in high-risk soft tissue sarcoma (STS) of an extremity or the trunk wal …
PURPOSE: To determine whether the administration of histology-tailored neoadjuvant chemotherapy (HT) was superior to the administration of s …
Efficacy of trabectedin for the treatment of liposarcoma.
Zijoo R, von Mehren M. Zijoo R, et al. Expert Opin Pharmacother. 2016 Oct;17(14):1953-62. doi: 10.1080/14656566.2016.1229304. Epub 2016 Sep 15. Expert Opin Pharmacother. 2016. PMID: 27615729 Review.
INTRODUCTION: Trabectedin (ET-743) is a synthetic marine derived alkylating agent, extracted originally from a Caribbean Sea sponge. ...Numerous Phase I, II and III clinical trials have been conducted with Trabectedin. It has been studied as mon …
INTRODUCTION: Trabectedin (ET-743) is a synthetic marine derived alkylating agent, extracted originally from a Caribbea …
174 results